Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$28.18 USD

28.18
2,038,454

-0.20 (-0.71%)

Updated May 3, 2024 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

by Zacks Equity Research

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.

Dentsply International (XRAY) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 28.95% and 3.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.

Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised

by Zacks Equity Research

Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.

XRAY or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. MMSI: Which Stock Is the Better Value Option?

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

by Zacks Equity Research

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

Here's Why You Should Bet on Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across its segments and prudent acquisitions.

BD Introduces New Product to Reduce the Risk of Sepsis

by Zacks Equity Research

BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.

Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

Strong prospects in emerging markets provide DENTSPLY (XRAY) a competitive edge in the MedTech space.

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Dentsply (XRAY) Up 18.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Top Ranked Momentum Stocks to Buy for March 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st

XRAY vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Will DENTSPLY SIRONA Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in DENTSPLY SIRONA.

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.

Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Near-Term Outlook for Dental Supplies Industry Looks Bright

by Zacks Equity Research

The wave of digital transformation is shaping the future of dental supply companies.

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

Why Is Dentsply (XRAY) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for December 7th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today